Your link to the latest news on research, treatment, prevention and education from the state's only

National Cancer Institute-designated Comprehensive Cancer Center

Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex® and Lipitor® - used respectively for arthritis pain and lowering cholesterol - shows that these drugs are well tolerated in the treatment of recurrent prostate cancer. Preliminary results from an ongoing Phase II clinical trial will be presented during the 2012 Genitourinary Cancers Symposium, which begins Thursday in San Francisco.Read more

Receiving a boost to support its Breast Surgery Fellowship Program, The Cancer Institute of New Jersey has been awarded a $75,000 grant from The Breast Cancer Alliance for academic year 2012-2013. CINJ's one-year fellowship provides surgeons who have completed their general surgery residency with advanced training and experience that prepares them to provide state-of-the-art care specifically for patients with breast disease. The grant will support the work of CINJ's newest breast surgical fellow as of July.Read more

To mark its seventh year, the Century for the Cure bike ride continues to break records, surpassing previous years' efforts and raising $200,000 to directly benefit The Cancer Institute of New Jersey. A check presentation was recently held to recognize the efforts of ride founder and cancer survivor Scott Glickman and more than 135 cyclists and 100 volunteers who participated in the event, which supports cancer research and treatment at CINJ.Read more

CINJ Office of Communications  ·  195 Little Albany Street  ·  New Brunswick, NJ  ·  732-235-9871